Notice
2026/04/15
OSAKA, Japan, April 15, 2026 - Shionogi & Co., Ltd. today announced that it has made an equity investment in Restore Vision Inc. (“Restore Vision”), a Tokyo-based startup company developing innovative technologies in the field of ophthalmology. This investment represents Shionogi’s first investment under its Corporate Venture Capital (CVC) activities.
In April 2025, Shionogi established its Corporate Venture Capital (CVC) to explore next-generation growth opportunities in new markets and technology areas. The CVC targets a broad range of investment areas beyond pharmaceuticals, including technology, infrastructure, and resources. Through these activities, Shionogi seeks to create new value that contributes to addressing social challenges and advancing healthcare. Through its CVC activities, Shionogi aims to build early-stage partnerships with startup companies that possess innovative technologies and business ideas, supporting them by leveraging Shionogi’s research and development capabilities, business experience, and network—thereby fostering relationships that contribute to mutual growth.
Website: https://www.shionogi.com/global/en/innovation/cvc.html
About Restore Vision
Restore Vision Inc. is a startup company aiming to realize a visual restoration gene therapy using its unique functional gene coding “Chimeric Rhodopsin,” which is a protein-based optical sensor. The company’s technology is expected to contribute to addressing social challenges associated with blindness caused by retinal disorders, for which effective preventive or curative treatments have not yet been established, including the hardships experienced by patients and the burden on those around them.
Company Overview
Restore Vision Inc.
Headquarters: Toranomon Hills Business Tower 15F, 1-17-1 Toranomon, Minato-ku, Tokyo, Japan
Management: Yusaku Katada, CEO / Hikaru Miyazaki, COO
Established: November 14, 2016
Business: Research and development of regenerative medicine products
Website: https://restore-vis.com/
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html